DEFA14A: ATAI Life Sciences Reports Strong Q2, BPL-003 Success

ATAI Life Sciences announced positive Phase 2b results for BPL-003 in TRD, a planned strategic combination with Beckley Psytech, and extended cash runway into H2 2027.

Summary

• Reported second quarter 2025 financial results and corporate updates, including a planned strategic combination with Beckley Psytech Limited.
• Announced positive topline data from the core, blinded stage of the Phase 2b clinical trial of BPL-003 (intranasal mebufotenin benzoate) in patients with treatment-resistant depression (TRD).
• BPL-003 met its primary and all key secondary endpoints, demonstrating rapid, robust, and durable antidepressant effects for up to 8 weeks with a single dose.
• Cash, cash equivalents, short-term securities, public equity holdings, and digital assets are expected to fund combined company operations into the second half of 2027.
• Net loss attributable to stockholders for the three months ended June 30, 2025, was $27.7 million, a significant reduction from $57.3 million for the same period in 2024.
• Cash, cash equivalents, and short-term securities increased to $95.9 million as of June 30, 2025, from $72.3 million as of December 31, 2024.
• Topline data for VLS-01 (buccal film DMT) in TRD is now anticipated in the second half of 2026 due to slower-than-anticipated site activation and recruitment.
• Recognify Life Sciences' Inidascamine (formerly RL-007) Phase 2b clinical trial for cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint with statistical significance.

Sentiment

Score: 8

Explanation: The positive Phase 2b results for BPL-003, a lead asset, represent a significant de-risking event. The planned strategic merger with Beckley Psytech strengthens the pipeline and market position, while the extended cash runway provides substantial financial stability. Although there are delays with VLS-01 and a setback with Inidascamine, the overall strategic direction and clinical progress of the core psychedelic pipeline are highly encouraging.

Positives

• Positive topline data from the Phase 2b clinical trial of BPL-003 in TRD, meeting its primary and all key secondary endpoints.
• BPL-003 demonstrated rapid, robust, and durable antidepressant effects for up to 8 weeks with a single dose and was generally well-tolerated.
• Planned strategic combination with Beckley Psytech is expected to solidify ATAI's position as a global leader in psychedelic-based mental health therapies.
• Cash, cash equivalents, and short-term securities increased to $95.9 million as of June 30, 2025, from $72.3 million as of December 31, 2024.
• Cash runway for the combined company operations is extended into the second half of 2027.
• Net loss attributable to stockholders significantly decreased to $27.7 million for Q2 2025 from $57.3 million for Q2 2024.
• Recent fundraises totaling nearly $140 million so far this year reflect strong confidence in the company's strategy.
• Discovery of novel 5-HT2A receptor agonists with non-hallucinogenic potential, expanding the drug discovery pipeline.

Negatives

• Topline data for VLS-01 Phase 2 trial is delayed to the second half of 2026 due to slower-than-anticipated site activation and recruitment.
• Inidascamine (Recognify Life Sciences) Phase 2b clinical trial did not meet its primary endpoint with statistical significance.
• ATAI intends to allocate resources to its wholly owned psychedelic pipeline, indicating a potential deprioritization or divestment of Inidascamine.
• General and administrative (G&A) expenses increased by $1.5 million year-over-year, primarily due to legal and professional services related to the planned merger and corporate domicile move.

Risks

• The proposed strategic combination with Beckley Psytech Limited and the corporate redomiciliation (Proposed Transactions) may not be completed in a timely manner or at all.
• There is a risk that any required shareholder approvals for the Proposed Transactions are not obtained.
• The anticipated benefits of the Proposed Transactions may not be fully realized.
• Any or all of the various conditions to the consummation of the Proposed Transactions may not be satisfied or, in the case of the acquisition of Beckley Psytech, waived.
• The occurrence of any event, change, or other circumstance could give rise to the termination of the share purchase agreement.
• The corporate redomiciliation could affect the trading, liquidity, and price of atai securities.
• The announcement or pendency of the Proposed Transactions may impact atai's ability to retain and hire key personnel, or its operating results and business generally.

Future Outlook

The company expects topline data from the BPL-003 open-label extension and Phase 2a studies in Q3 2025, with an End-of-Phase 2 meeting request to the FDA also planned for Q3 2025. Shareholder approval for the strategic combination with Beckley Psytech is anticipated in Q4 2025. Topline data for EMP-01 is expected in Q1 2026, while VLS-01 data is now pushed to H2 2026. The combined company's cash runway is projected into H2 2027. The company also plans to analyze Inidascamine data and evaluate strategic options, and is moving its corporate domicile to the U.S. for efficiency.

Management Comments

• Srinivas Rao, CEO: "The planned strategic combination with Beckley Psytech is expected to solidify our position as the global leader in the psychedelic mental health space. By combining our experienced teams and psychedelic expertise as well as adding a late-stage, clinically-validated asset like BPL-003 to our pipeline... we are accelerating our ability to bring novel, effective treatments to patients in need."
• Srinivas Rao, CEO: "The recent positive Phase 2b results for BPL-003 highlight its potential as a differentiated, fast-acting, and durable option for treatment-resistant depression that aligns with the established 2-hour interventional psychiatry treatment paradigm."
• Christian Angermayer, Co-founder and Chairman: "The second quarter marks a pivotal moment for atai and the broader psychedelic sector... Our recent fundraises, totaling nearly $140 million so far this year, reflect strong confidence in our strategy and enable us to advance our pipeline with the urgency this mental health crisis demands."

Industry Context

The announcement underscores the growing recognition and scientific validation of psychedelics as a transformative approach to mental health care. The planned strategic combination with Beckley Psytech aims to create a global leader in the emerging market for short in-clinic psychedelic-based mental health therapies, aligning with broader industry trends of consolidation and late-stage asset acquisition in the biopharmaceutical sector.

Comparison to Industry Standards

• BPL-003's alignment with the established 2-hour interventional psychiatry treatment paradigm positions it favorably for integration into existing healthcare systems, though specific comparative efficacy against other TRD treatments (e.g., esketamine, traditional antidepressants) is not detailed.
• The Phase 2b study of BPL-003 is noted as the largest ever controlled study of mebufotenin and the only blinded Phase 2 study of mebufotenin to include sites in the United States, indicating a leading position in this specific compound's development.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased value through strategic merger and successful clinical development; requirement for shareholder approval for the merger and domicile move; potential dilution from equity issuances.
• Patients: Accelerated development and potential availability of novel, effective treatments for mental health conditions, particularly TRD and SAD.
• Employees: Potential for integration challenges and retention risks associated with the merger and corporate redomiciliation.
• Creditors: Payoff of Hercules debt facility reduces debt burden.

Next Steps

• Anticipate topline data from BPL-003 open-label extension stage in Q3 2025.
• Anticipate topline data from BPL-003 open-label Phase 2a study in Q3 2025.
• Submit End-of-Phase 2 meeting request to the U.S. Food and Drug Administration (FDA) for BPL-003 in Q3 2025.
• Progress the planned strategic combination with Beckley Psytech Limited to shareholder approval stage in Q4 2025.
• Anticipate topline data for EMP-01 Phase 2 study in Q1 2026.
• Anticipate topline data for VLS-01 Phase 2 trial in H2 2026.
• Analyze the full data set and evaluate strategic options for Inidascamine.
• Further optimize and study novel 5-HT2A receptor agonists in animal models.
• Continue the process to move the corporate domicile to the U.S.

Key Dates

Recommendation

The positive Phase 2b results for BPL-003 represent a significant de-risking event for a lead asset targeting treatment-resistant depression, a high-need indication. The planned strategic merger with Beckley Psytech strengthens the company's pipeline and market position, creating a more robust entity in the psychedelic mental health space. The extended cash runway into the second half of 2027 provides substantial financial stability, alleviating immediate funding concerns. While there are setbacks with VLS-01 delays and Inidascamine's primary endpoint not being met, the overall strategic direction and clinical progress of the core psychedelic pipeline are highly encouraging for long-term growth and value creation.

Keywords

atai Life Sciences, Beckley Psytech, BPL-003, mebufotenin, treatment-resistant depression, TRD, psychedelics, mental health, clinical trial, Phase 2b, VLS-01, DMT, EMP-01, R-MDMA, social anxiety disorder, SAD, 5-HT2A receptor agonists, Inidascamine, CIAS, merger, biopharmaceutical, FDA, cash runway, financial results